Timothy Bell, MHA

SpringWorks Therapeutics, Inc.
Stamford, Connecticut, United States

Disclosure information not submitted.

Presentation(s):

• Paper 102 - EFFICACY OF NIROGACESTAT IN PATIENTS WITH DESMOID TUMORS AND POOR PROGNOSTIC FACTORS: PATIENT-REPORTED OUTCOMES, PROGRESSION-FREE SURVIVAL, AND OBJECTIVE RESPONSE RATE IN THE PHASE 3 DEFI TRIAL

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST